incretin mimetic agents glp 1 receptor agonists Effects of incretin-based therapies on bone metabolism. GLP-1 Incretin and insulin signaling as
Description
& Lohmander, L
10.1210/endo-115-6-2176 56 HolstJ
69705-5/asset/079012c9-a24f-4391-ba39-2f5d03668f6f/main.assets/gr1_lrg.jpg)
[10] That's a pretty big incidence rate
doi: 10.1159/000521264 Summary Keywords GLP-1R agonists, obesity, weight-reducing drugs, metabolic diseases, dual agonism Citation Wang J-Y, Wang Q-W, Yang X-Y, Yang W, Li D-R, Jin J-Y, Zhang H-C and Zhang X-F (2023) GLP1 receptor agonists for the treatment of obesity: Role as a promising approach
Semaglutide and dulaglutide were classified as early failure types, exenatide as a random failure type, and liraglutide as a wear-out failure type (Additional file 1: Table S5 for raw data)
